• Estrella Immunopharma received a Nasdaq notice on Aug. 17, 2026 for failing the $1 minimum bid rule.
• Shares traded below $1 for 30 straight business days from July 6, 2026 through Aug. 14, 2026.
• Stock keeps trading on Nasdaq Capital Market under ESLA, pending a cure by Feb. 16, 2027.
• Compliance requires a $1 bid for at least 10 consecutive business days; Nasdaq can require up to 20.
• Failure to regain compliance could trigger delisting proceedings; a reverse stock split remains an option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-092657), on August 21, 2026, and is solely responsible for the information contained therein.